Navigation Links
Long-acting insulin analogues in type 2 diabetes: advantage over human insulin not proven
Date:4/3/2009

It has so far not been proven that long-acting insulin analogues (LAIAs) have an advantage over conventional human insulin in the treatment of patients with type 2 diabetes. Even though the results of a 5-year study are available for one of the two LAIAs assessed (insulin glargine), the potential long-term benefits and harms of this drug class have still not been sufficiently investigated. This is the conclusion of a report by the German Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, which was published in March 2009 and for which an English-language summary is now available.

The final report is part of a comprehensive commission package awarded by the Federal Joint Committee, by means of which key therapy options for people with diabetes are to be assessed. The reports on rapid-acting insulin analogues in diabetes mellitus type 1 and 2 have already been completed.

Only one study lasting longer than 12 months was available

For the assessment of the LAIAs, IQWiG searched for studies that either compared one of the two currently approved LAIAs for the treatment of type 2 diabetes (insulin glargine and insulin detemir) with human insulin, or compared the benefits of the two LAIAs with each other. A precondition for study inclusion was that patients had been randomly allocated to one of the treatment groups and that the treatment period had lasted at least 24 weeks, as the aim of the project was to assess the potential benefits and harms of long-term therapy.

A database search and queries to the manufacturers resulted in the retrieval of a total of 18 studies for inclusion in the evaluation. Of these studies, 15 (glargine: 9; detemir: 6) compared an LAIA with neutral protamine Hagedorn (NPH) insulin, a longer-acting (intermediate-acting) insulin based on human insulin. The other 3 studies compared the two LAIAs with each other. In 11 studies, insulin was used in addition to oral antidiabetics, in 6
'/>"/>

Contact: Dr. Anna-Sabine Ernst
info@iqwig.de
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. US Back Pain Market Approaches $23 Billion in 2018 - Anticipated Long-Acting, Abuse-Resistant Opioids Drive Value
2. Inspirational Teams of Athletes with Diabetes Build Momentum in 2009 with Sponsorship from Long-Acting Insulin Lantus(R) and Rapid-Acting Insulin Apidra(R)
3. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
4. Studies Ignite Hope for Long-Acting Allergy Vaccines
5. FDA Issues Not-Approvable Letter for Lillys Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
6. Plain-Language Guides Detail Insulin Treatments
7. OmniPod(R) Insulin Management System Wins 2009 Edison Best New Product Award
8. NICE SUGAR: Intensive insulin therapy risks
9. Insulin Pens and Growing Diabetic Community Increase Market for Insulin Delivery Devices in Europe, Says Frost & Sullivan
10. Gene Explains How High-Fructose Diets Lead to Insulin Resistance
11. Ethnicity May Drive Response to Obesity, Insulin Resistance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... the US consumer product safety commission. This number is far ... are mainly related to the children as they are the ... in an increase in the emergency room visit. ... the sidewalk, through crowded malls and playgrounds. , ...
... cause of concern as most of them are related to ... health problems due to which people abstained from work. ... and Development (CIPD) on about 30,000 workers revealed that mental ... to muscle related problems like bad back. ,The ...
... of Alzheimer's disease nationwide, both the New York State ... a resolution aimed at raising awareness of the importance ... brain disorder. ,The resolution declared November 2007 ... as Memory Screening Day in New York State. ...
... Advanced Bio-Surfaces, Inc., (ABS) an orthopedic implant developer and ... been completed in the United States using the OrthoGlide ... implant designed to relieve chronic, disabling pain, due to ... ,"There has been a significant increase in ...
... products and medicines has the potential to reach Rs.120 billion ... of exclusive export promotion zones (EPZ) across India, says ... accelerated with the setting up of EPZs in about 12 ... over 25 percent in countries like the US, Britain, Spain, ...
... also known as marijuana or ganja, can help in ... occur when body tissues are attacked by its own ... at the University of Bonn, used tetrahydrocannabinol (THC), the ... and found that it reduced skin allergies. ...
Cached Medicine News:Health News:1,600 Roller Shoe Injuries Reported 2Health News:Mental Illness Foremost Reason for Absenteeism 2Health News:New York Legislature Highlights for Awareness of Alzheimer's Disease 2Health News:New York Legislature Highlights for Awareness of Alzheimer's Disease 3Health News:Export of Herbal Products to Reach Rs.120 Billion by 2012: Study 2
(Date:12/24/2014)... NEW YORK and LONDON ... in global orthopedic industry are expected to grow at ... consumption in terms of value and volume. Hip, knee ... the developed world while in emerging economies they have ... failure rates are challenging the use of composites. Non-metallic ...
(Date:12/24/2014)... DIEGO , Dec. 23, 2014 ResMed (NYSE: ... significant patent infringement action against Chinese medical device manufacturer BMC ... (ITC) ruled today that BMC,s masks listed below infringe ResMed,s ... or selling these masks in the United States ... iVolve N2 nasal mask , Willow nasal pillows mask ...
(Date:12/24/2014)... , Dec. 23, 2014  Lockton Dunning Benefits, ... Lockton Companies, announced the addition of Vice President ... join Lockton Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... relevant industry experience to the position.  Most recently, ... Sales at Diplomat Specialty Pharmacy, where she has ...
Breaking Medicine Technology:Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Kim Foerster Joins Lockton Companies 2
... Calif., May 18, 2011 Bayer HealthCare Pharmaceuticals, ... ONXX ) today announced results from a Phase ... with locally advanced or metastatic breast cancer previously ... Nexavar was associated with statistically significant improvements in ...
... SEATTLE, May 18, 2011 Dendreon Corporation (Nasdaq: ... poster presentation detailing clinical trial plans for PROVENGE® (sipuleucel-T) and ... upcoming American Society for Clinical Oncology annual meeting in Chicago, ... on Monday, June 6, 2011, from 8:00 a.m. to 12:00 ...
Cached Medicine Technology:Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 2Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 3Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 4Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 5Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 6Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 7Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 8Dendreon Announces Clinical Trial Plans for PROVENGE and DN24-02 at the American Society of Clinical Oncology Annual Meeting 2Dendreon Announces Clinical Trial Plans for PROVENGE and DN24-02 at the American Society of Clinical Oncology Annual Meeting 3Dendreon Announces Clinical Trial Plans for PROVENGE and DN24-02 at the American Society of Clinical Oncology Annual Meeting 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: